Immunological aspects of head and neck cancer: Biology, pathophysiology and therapeutic mechanisms

Surgeon

Volumn 2, Issue 4, 2004, Pages 187-207

  McKechnie, A ^a   Robins, R A ^a   Eremin, O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Head and neck cancer; Immune dysfunction; Immunotherapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; BCG VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIN; DACARBAZINE; DIPHTHERIA TOXIN; DOXORUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GANCICLOVIR; IMMUNOGLOBULIN FC FRAGMENT; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 2; LEVAMISOLE; METHOTREXATE; MONOCLONAL ANTIBODY; PRODRUG; RADIOISOTOPE; RECOMBINANT INTERLEUKIN 2; TEGAFUR; THIOTEPA; THYMOSIN ALPHA1; UNINDEXED DRUG; URACIL; ZINC;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ARTHRALGIA; BCG VACCINATION; BIOLOGY; BONE MARROW DISEASE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHILL; CLINICAL TRIAL; DENDRITIC CELL; EVIDENCE BASED MEDICINE; FEVER; FREQUENCY ANALYSIS; GENE DELIVERY SYSTEM; HEAD AND NECK CANCER; HEADACHE; HOST RESISTANCE; HUMAN; LYMPHOCYTOPENIA; MALAISE; METASTASIS; MORBIDITY; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SOLID TUMOR; SYSTEMIC DISEASE; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 4344579580     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(04)80001-5     Document Type: Review

References (226)

1. C.R.C., Cancer Research Campaign. 2001.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827-41.
3. Candela FC, Kothari K, Shah JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck. 1990; 12:197-203.
4. Shah JP, Candela FC, Poddar AK. The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer, 1990; 66: 109-13.
5. Woolgar JA, Scott J, Vaughan ED, Brown JS, West CR. Rogers S. Survival, metastasis and recurrence of oral cancer in relation to pathological features. Ann R Coll Surg Engl. 1995; 77: 325-31.
6. Khalil MY, Grandis JR, Shin DM. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer Expert Rev Anticancer Ther 2003; 3: 367-80.
7. Ganly I, Soutar DS, Kaye SB. Current role of gene therapy in head and neck cancer. Eur J Surg Oncol. 2000; 26: 338-43.
8. Trinchieri, G, Biology of natural killer cells. Adv Immunol. 1989; 47:187-376.
9. Roitt IM, Brostoff J, Male DK. Immunology. 6th ed. 2001. Edinburgh; New York: Mosby. 480.
10. Colucci F, Scweighoffer F, Tomasello E, Turner M, Ortaldo JR, Vivier E et al. Natural cytotoxity uncoupled from the Syk and ZAP-70 intracellular kinases. Nat Immunol. 2002; 3: 288-94.
11. Ortaldo JR, Winkler-Pickett R, Willette-Brown J, Wange RL, Anderson SK, Palumbo GJ. et al. Structure/function relationship of activating Ly-49D and inhibitory Ly-49G2 NK receptors, J Immunol. 1999;163:5269-77.
12. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol. 1998; 160: 4951-60.
13. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol, 1996; 14: 619-48.
14. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990; 248: 220-3.
15. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997; 94: 11520-5.
16. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003; 3: 781-90.
17. Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. The mononuclear phagocyte system revisited. J Leukoc Biol, 2002; 72:621-7.
18. Ryan GR, Dai XM, Dominguez MG, Tong W, Chaun F, et al. Rescue of the colony-stimulating factor I (CSF-1)-nullizygous mouse (Csf1(op)/Csf1(op)) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis. Blood, 2001; 98: 74-84.
19. Kennedy DW, Abkowitz JL. Mature monocytic cells enter tissues and engraft. Proc Natl Acad Sci USA, 1998; 95:14944-9.
20. Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood, 1997; 90: 986-93.
21. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J, 1995; 9: 866-73.
22. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J, 1994; 8:504-12.
23. Duffield JS. The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond), 2003; 104: 27-38.
24. Jun CD, Yoon HJ, Kim HM, Chung HT. Fibronectin activates murine peritoneal macrophages for tumor cell destruction in the presence of IFN-gamma. Biochem Biophys Res Commun, 1995; 206: 969-74.
25. Saio M, Radoja S, Marino M, Frey AB. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol, 2001; 167:5583-93.
26. Brown SB, Savill J. Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol, 1999;162:480-5.
27. Gibbs DF, Johnson KJ, Varani J, Warner RL, Weiss SJ. Characterization of matrix metalloproteinases produced by rat alveolar macrophages. Am J Respir Cell Mol Biol, 1999; 20:1136-44.
28. Song E, Duyang N, Horbelt M, Antus B, Wang M, Exton MS. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol, 2000; 204: 19-28.
29. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol, l999; 17:593-623.
30. Dalgleish AG. O'Byrne KJ. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res, 2002; 84:231-76.
31. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer, 2001; 85:473-83.
32. Sharma RA, Dalgliesh AG, Steward WP, O'Byrne KJ. Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). Oncol Rep, 2003; 10:1625-31.
33. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis, 1999; 5: 285-94.
34. Hogg KG, Kumkate S, Anderson S, Mountford AP. Interleukin-12 p40 secretion by cutaneous CD11c+ and F4/80+ cells is a major feature of the innate immune response in mice that develop Th1-mediated protective immunity to Schistosoma mansoni. Infect Immun, 2003: 71:3563-71.
35. Park AY. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol, 2000; 165: 896-902.
36. Scharton-Kersten T, Alfonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol, 1995; 154:5320-30.
37. Desmedt M, Rottiers P, Dooms H, Fiers W, Gooten J. Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses. J Immunol, 1998; 160: 5300-8.
38. Jones E, Golgher D, Simon AK, Dahm-Vicker M, Screaton G, Elliott T, Gallimore A. The influence of CD25+ cells on the generation of immunity to tumour cell lines in mice. Novartis Found Symp, 2004; 256:149-52, discussion 152-7, 259-69.
39. Wang HY, Lee DA, Leng G, Guo Z, Li Y. Kiniwa Y et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity, 2004; 20:107-18.
40. Takahashi T, Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease. Curr Mol Med, 2003; 3:693-706.
41. Steinman RM. Some interfaces of dendritic cell biology. APMIS, 2003;111: 675-97.
42. Satthaporn S, Eremin O. Dendritic cells (I): Biological functions. J R Coll Surg Edinb, 2001; 46:9-19.
43. Zhou LJ, Tedder TF. A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. Blood, 1995; 86: 3295-301.
44. Macatonia SE, Hosken WA, Litton M, Vieira P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol, 1995; 154: 5071-9.
45. Grouard G, Durand I, Filgueira L, Banchereau J, Lin YJ. Dendritic cells capable of stimulating T cells in germinal centres. Nature, 1996. 384:364-7.
46. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cells stimulatory capacity: T-T help via APC activation. J Exp Med, 1996; 184: 747-52.
47. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol, 1999; 11:203-10.
48. Garrido E, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res, 2001; 83:117-58.
49. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med, 1982; 155:1823-41.
50. Steinman, R.M., The dendritic cell system and its role in immunogenicity. Annu Rev Immunol, 1991. 9: p. 271-96.
51. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med, 1973; 137:1142-62.
52. Burnet FM. The concept of immunological surveillance. Prog. Exp. Tumour Res., 1970; 13:1-27.
53. Chang WY. Complete spontaneous regression of cancer: four case reports, review of literature, and discussion of possible mechanisms involved. Hawaii Med J, 2000; 59: 379-87.
54. Uyttenhove C, Van Snick J, Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J Exp Med, 1980; 152:1175-83.
55. Boon T, Van Snick J, Van Pel A, Uyhenhove C, Marchand M. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med, 1980; 152: 1184-93.
56. Maryanski JL, Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. Eur J Immunol, 1982; 12: 406-12.
57. Maryanski JL, Van Snick J, Cerottini JC, Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol, 1982; 12: 401-6.
58. Grakoui A, Bromley SK, Sumen C, Daris MM, Shaw AS, Allen PM et al. The immunological synapse: a molecular machine controlling T cell activation. Science, 1999; 285:221-7.
59. Koch WM. Clinical implications of biomarkers in head and neck cancer. Curr Oncol Rep, 1999; 1:129-37.
60. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med, 2001; 344:1125-31.
61. Sand LP, Jalouli J, Larsson PA, Hirsch JM. Prevalence of Epstein-Barr virus in oral squamous cell carcinoma, oral lichen planus, and normal oral mucosa, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2002; 93: 586-92.
62. Lagarkova MA, Boitchenko VE, Mescheryakov AA, Kashkarova UA, Nedospasov SA. Human cortactin as putative cancer antigen. Oncogene, 2000; 19:5204-7.
63. Akervall J, Borg A, Diktor M, Jin C, Jin Y, Tanner M et al. Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck. Int J Oncol, 2002; 20: 45-52.
64. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell, 1989; 57: 327-34.
65. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer, 1989; 43:1072-6.
66. Matzinger P. An innate sense of danger. Semin Immunol, 1998; 10:399-415.
67. Leng Q, Bentwicz Z. Beyond self and nonself: fuzzy recognition of the immune system. Scand J Immunol, 2002; 56:224-32.
68. Matzinger P. The danger model: a renewed sense of self. Science, 2002; 296: 301-5.
69. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA, 2001; 98:8809-14.
70. Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z et al. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res, 2002; 62:5049-57.
71. Nakayama J, Tahara H, Tahara F, Saito M, Ito K, Nakamura H et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet, 1998; 18:65-8.
72. Vaziri H, Schachter F, Uchida I, Wei L, Zhu X, Effros R et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet, 1993; 52:661-7.
73. Chiu CP, Harley CB. Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc Soc Exp Biol Med, 1997; 214:99-106.
74. Bodnar AG, Duellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al. Extension of life-span by introduction of telomerase into normal human cells. Science, 1998; 279:349-52.
75. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene, 2001; 269: 1-12.
76. Blasco MA, Hahn WC. Evolving views of telomerase and cancer. Trends Cell Biol, 2003; 13:289-94.
77. Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jiminez P, Marchand M et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens, 1998; 52:520-9.
78. Seliger B, Ritz U, Abele R, Bocke M, Tampe R, Sutter G et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res, 2001; 61(24):8647-50.
79. Ryu KS, Lee YS, Kim BK, Park YG, Kim YW, Hur SY et al. Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers. Exp Mol Med, 2001; 33(3):136-44.
80. Andratschke M, Pauli C, Stein M, Chaubal S, Wollenberg B et al. MHC-class I antigen expression on micrometastases in bone marrow of patients with head and neck squamous cell cancer. Anticancer Res, 2003; 23(2B): 1467-71.
81. Coulie PG, Ikeda H, Baurain JF, Chiari R. Antitumor immunity at work in a melanoma patient. Adv Cancer Res, 1999; 76:213-42.
82. Rouas-Freiss N, Paul P, Daussset J, Carosella ED. HLA-G promotes immune tolerance. J Biol Regul Homeost Agents, 2000; 14(2):93-8.
83. Adrian Cabestre F, Moreau P, Riteau B, Ibrahim EC, Le Danff C, Dausset J et al. HLA-G expression in human melanoma cells: protection from NK cytolysis. J Reprod Immunol, 1999; 43(2):183-93.
84. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer, 2001; 85(7): 1047-54.
85. Liu QY, Rubin MA, Omene C, Lederman S, Stein CA. Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res, 1998; 4(7):1803-11.
86. Frankel B, Longo SL, Canute GW. Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion. J Neurooncol, 2000; 48(1):21-6.
87. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res, 2002; 8(8):2553-62.
88. Nat R, Radu E, Regalia T, Popescu LM. Apoptosis in the immune system: 1. Fas-induced apoptosis in monocytes-derived human dendritic cells. J Cell Mol Med, 2002. 6(2):223-34.
89. Murray JC, Symonds P, Ward W, Huggins M, Tiga A, Rice K et al. Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II-dependent mechanism. J Immunol, 2004. 172(1): p. 274-81.
90. Murray JC, Heng YM, Symonds P, Ward W, Huggins M, Rice K et al. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis. J Leukoc Biol, 2004; 75(5):772-76.
91. Logullo AF, Nonogaki S, Miguel RE, Kowalski LP, Nishimoto IN, Pasini FS et al. Transforming growth factor beta1 (TGFbeta1) expression in head and neck squamous cell carcinoma patients as related to prognosis. J Oral Pathol Med 2003; 32(3):139-45.
92. Pasini FS, Brentani MM, Kowalski LP, Federico MH. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck, 2001; 23(9):725-32.
93. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal ME, He XY et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A, 1997; 94(21):11514-9.
94. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ et al. MIC-1 Serum Level and Genotype: Associations with Progress and Prognosis of Colorectal Carcinoma. Clin Cancer Res, 2003; 9(7):2642-50.
95. Karan D, Chen SJ, Johansson SL, Singh AP, Paralkar VM, Lin MF et al. Dysregulated expression of MIC-1/PDF in human prostate tumor cells. Biochem Biophys Res Commun, 2003; 305(3):598-604.
96. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1 in glioblastoma cells independently of p53 and HIF-1. Oncogene, 2002; 21(27):4212-19.
97. Marjono AB, Brown DA, Horton KE, Wallace EM, Breit SN, Manuelpillai U. Macrophage inhibitory cytokine-1 in gestational tissues and maternal serum in normal and pre-eclamptic pregnancy. Placenta, 2003; 24(1):100-6.
98. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer, 1999; 85(3):554-61.
99. Kannan K, Amariglio N, Rechavi G, Givol D. Profile of gene expression regulated by induced p53: connection to the TGF-beta family. FEBS Lett, 2000; 470(1):77-82.
100. Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer, 1993; 55(1):96-101.
101. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood, 1998; 92(12):4778-91.
102. Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res, 1999; 59(20): 5356-64.
103. al-Sarireh B, Eremin O. Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J R Coll Surg Edinb, 2000; 45(1):1-16.
104. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell, 1992; 71(7):1065-68.
105. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today, 1994, 15(7):321-31.
106. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol, 1996; 14:233-58.
107. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 1992; 71(7):1093-102.
108. Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F et al. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules. Cancer Res, 1999; 59(11):2650-56.
109. Hellstrom KE, Hellstrom I, Chen L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev, 1995; 145:123-45.
110. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science, 1993; 259(5093): 368-70.
111. Cavallo F, Martin-Fontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P et al. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol, 1995; 25(5): 1154-62.
112. La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism. J Immunol, 1999; 162(8):4817-23.
113. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dorken B. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol, 1997; 159(8):3808-15.
114. Kuss I, Saito T, Johnson JT, Whiteside TL. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res, 1999; 5(2): 329-34.
115. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res, 1995; 1(11):1327-35.
116. Burshtyn DN, Shin J, Stebbins C, Long EO. Adhesion to target cells is disrupted by the killer cell inhibitory receptor. Curr Biol, 2000; 10(13):777-80.
117. Wanebo HJ, Blackinton D, Koultab N, Mehta S. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer. Am J Surg, 1993; 166(4): 389-94.
118. Melioli G, Semino C, Margarino G, Mereu P, Scala M, Cangemi G et al. Expansion of natural killer cells in patients with head and neck cancer: detection of "noninhibitory" (activating) killer Ig-like receptors on circulating natural killer cells. Head Neck, 2003; 25(4):297-305.
119. Bauernhofer T, Kuss I, Henderson B, Baum AS, Whiteside TL. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol, 2003; 33(1):119-24.
120. Satthaporn S, Eremin O. Dendritic cells (II): Role and therapeutic implications in cancer. J R Coll Surg Edinb, 2001; 46(3):159-67.
121. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer, 2001;91(11): 2136-47.
122. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res, 2000; 6(5):1755-66.
123. Hasebe H, Nagayama H, Sato K, Enomoto M, Takeda Y, Takahashi TA. Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients. Biomed Pharmacother, 2000; 54(6):291-98.
124. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight D SC. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol, 2001; 166(1):678-89.
125. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res, 1997; 3(3):483-90.
126. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med, 1999; 190(10):1417-26.
127. Gabrilovich DI, Chen HL, Girgis KR. Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med, 1996; 2(10): 1096-103.
128. Ohm JE, Shurin MR. Esche C, Lotze MT. Carbone DP et al. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol, 1999; 163(6):3260-68.
129. Ninck S. Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 2003; 106(1):34-44.
130. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol, 2000;18(10):2046-52.
131. Kikuchi K, Kusama K, Taguchi K. Ishikawa F, Okamoto M, Shimada J et al. Dendritic cells in human squamous cell carcinoma of the oral cavity. Anticancer Res, 2002; 22(2A):545-57.
132. Deng Y, Yuan X. Chen Z. [Immunobiological significance of S-100 protein positive dendritic cells (S-100+DC) in patients with oral squamous cell carcinoma]. Zhonghua Kou Qiang Yi Xue Za Zhi, 1997; 32(3):174-76.
133. Enk AH. Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer, 1997; 73(3): 309-16.
134. Coley WB. The treatment of malignant tumors by repeated inoculations of crysipelas. With a report of ten original cases. 1893. Clin Orthop, 1991(262): 3-11.
135. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther, 1994; 64(3):529-64.
136. Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol Nefrol, 2004; 56(1): 65-72.
137. Bohle A. Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology, 2004; 63(4):682-86; discussion 686-87.
138. Vonderheide RH. Domchek SM, Schultze JL, George DJ, Hoar KM. Chen DY et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res, 2004; 10(3): 828-39.
139. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest, 2003; 21(6):873-86.
140. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M et al. A phase I study of autologous dendntic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother, 2003; 52(3): 155-61.
141. Gitlitz BJ. Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother, 2003; 26(5):412-19.
142. Adams M, Navabi H, Jasani B, Man S, Fiander A, Evans AS et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine, 2003; 21(7-8): 787-90.
143. Chang AE, Redman BG. Whitfield JR. Nickoloff BJ, Braun TM, Lee PP et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res, 2002; 8(4):1021-32.
144. Hernando JJ, Park TW. Kubler K, Offergeld R, Schlebusch H, Bauknecht T. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother, 2002; 51(1):45-52.
145. Heiser A, Coleman D, Dannull J Yancey D, Maurice MA. Lallas CD et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest, 2002; 109(3):409-17.
146. Rosenberg SA, Rapp HJ. Intralesional immunotherapy of melanoma with BCG. Med Clin North Am, 1976; 60(3):419-30.
147. El-Domeiri AA, Nika B, Hisa WC, Crispen R, Sabet TY, Gupta TK et al. Effectiveness of systemic BCG therapy in advanced melanoma. Arch Surg, 1977; 112(3):257-9.
148. Parish CR. Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol, 2003; 81(2):106-13.
149. Bassi P. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol, 2002; 11(1-2):77-83.
150. Herr HW, Schwalb DM, Zhang ZF, Sagani PC, Fair WR, Whitmore WF et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol, 1995; 13(6):1404-8.
151. Lamm DL. BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol, 1995; 27 Suppl 1:2-8.
152. Taylor SGT, Sisson GA, Bytell DE, Raynor WJ et al. A randomized trial of adjuvant BCG immunotherapy in head and neck cancer. Arch Otolaryngol, 1983; 109(8):544-49.
153. Fukazawa H, Ohashi Y, Sekiyama S, Hoshi H, Abe M, Takahashi M et al. Multidisciplinary treatment of head and neck cancer using BCG, OK-432, and GE-132 as biologic response modifiers. Head Neck, 1994; 16(1):30-38.
154. Chang AE, Li Q, Jiang G, Teknos TN, Chepeha DB, Bradford CR. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer. Head Neck, 2003; 25(3):198-209.
155. Low TL, Goldstein AL. Thymosins: structure, function and therapeutic applications. Thymus, 1984; 6(1-2):27-42.
156. Garaci E, Pica F, Sinibaldi-Vallebona P. Pierimarchi P, Mastino A, Matteucci C et al. Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol, 2003; 3(8):1145-50.
157. Paul S, Sodhi A. Modulatory role of thymosin-alpha-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice. Immunol Lett, 2002; 82(3):171-82.
158. Ohta Y, Tezuka E, Tamura S, Yagi Y. Thymosin alpha 1 exerts protective effect against the 5-FU induced bone marrow toxicity. Int J Immunopharmacol, 1985; 7(5):761-68.
159. Bodey B. Thymic hormones in cancer diagnostics and treatment. Expert Opin Biol Ther, 2001; 1(1):93-107.
160. Rasi G, Terzoli F, Izzo F, Pierimarchi P. Ranuzzi M, Sinibaldi-Vallebona P et al. Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma. Melanoma Res, 2000; 10(2):189-92.
161. Garaci E, Lopez M, Bonsignore G, Della Giulia M, D'Aprile M, Favalli C et al. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer, 1995; 31A(13-14):2403-5.
162. Gray WC, Hasslinger BJ, Suter CM, Blanchard CL, Goldstein AL et al. Suppression of cellular immunity by head and neck irradiation. Precipitating factors and reparative mechanisms in an experimental model. Arch Otolaryngol Head Neck Surg, 1986; 112(11):1185-90.
163. Wolf GT, Peterson KA, Lovett EJ 3rd. In vitro immune modulation by thymosin alpha 1 in patients with head and neck squamous cell carcinoma. Head Neck Surg, 1985; 7(5):350-56.
164. Hadden J, Verastegui E, Barrera JL, Kurman M, Meneses A, Zinser JW et al. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol, 2003; 3(8):1073-81.
165. Deniz Ayli M, Ensari C, Ayli M, Mandiroglu F, Mut S. Effect of oral levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients. Nephron, 2000; 84(3):291-92.
166. Kayatas M. Levamisole treatment enhances protective antibody response to hepatitis B vaccination in hemodialysis patients. Artif Organs, 2002. 26(6): 492-96.
167. Kimball ES. Experimental modulation of IL-1 production and cell surface molecule expression by levamisole. Ann N Y Acad Sci, 1993; 685:259-68.
168. Szeto C, Gillespie KM, Mathieson PW. Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunolgy, 2000; 100(2):217-24.
169. Kimball ES, Fisher MC. Levamisole effects on major histocompatibility complex and adhesion molecule expression and on myeloid cell adhesion to human colon rumor cell lines. J Natl Cancer Inst, 1996; 88(2):109-16.
170. Holcombe RF, Milovanovic T, Stewart RM, Brodhag TM. Investigating the role of immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints. Cancer Detect Prev, 2001; 25(2):183-91.
171. Janik J, Kopp WC, Smith JW, Longo DL, Alvord WG, Sharfman WH et al. Dose-related immunologic effects of levamisole in patients with cancer. J Clin Oncol, 1993; 11(1):125-35.
172. Wanebo HJ, Hilal EY, Strong EW, Pinsky CM, Mike V, Oettgen HF. Adjuvant trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. Recent Results Cancer Res, 1978; 68:324-33.
173. Schwartz EL, Baptiste N, Megati S, Wadler S, Otter BA. 5-Ethoxy-2′-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression. Cancer Res, 1995; 55(16): 3543-50.
174. Ishihara M, Kubota T, Watanabe M, Kavano Y, Narai S, Yasui N
175. Mantz CA, Vokes EE, Kies MS, Mittel B, Witt ME, List MA et al. Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann Oncol, 2001; 12(3):343-47.
176. Lew JI, Gooding WE, Ribeiro U, Safatle-Ribeiro AV, Posner MC. Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. Arch Surg, 2001; 136(7):737-42; discussion 743.
177. Oh JL, Vokes EE, Kies MS, Mittal BB, Witt ME, Weichselbaum RR et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol, 2003; 14(4):564-69.
178. Mantovani G, Proto E, Massa E, Mulas C, Madeddu C, Mura L et al. Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Int J Oncol, 2002; 20(2):419-27.
179. Mantovani G, Maccio A, Massa E, Mulas C, Mudu MC, Massidda S et al. Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation. Int J Oncol, 2000; 16(6):1227-33.
180. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol, 1985; 135(4):2865-75.
181. Kang WK, Park C, Yoon HL, Kim YS, Yoon SS, Lee MH et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther, 2001; 12(6):671-84.
182. Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol, 2003; 21(13):2564-73.
183. Van Herpen CM, Huijbens R, Looman M, De Vries J, Marres H, Van de Ven J et al. Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. Clin Cancer Res, 2003; 9(8):2950-56.
184. O'Malley BW Jr, Sewell DA, Li D, Kosai K, Chen SH, Woo SL et al. The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol Endocrinol, 1997; 11(6):667-73.
185. Li D, Ronson B, Guo M, Liu S, Bishop JS, Van Echo DA et al. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer. Cancer Res, 2002; 62(14):4023-28.
186. Li D, Zeiders JW, Liu S, Guo M, Xu Y, Bishop JS et al. Combination nonviral cytokine gene therapy for head and neck cancer. Laryngoscope, 2001; 111(5): 815-20.
187. Li S, Zhang X, Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst, 2002; 94(10):762-68.
188. Lin WC, Yasumura S, Suminami Y, Sung MW, Nagashima S, Stanson J et al. Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth. J Immunol, 1995; 155(10):4805-16.
189. Weidmann E, Sacchi M, Plaisance S, Heo DS, Yasumura S, Lin WC et al. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res, 1992; 52(21):5963-70.
190. Lin WC, Yasumura S, Whiteside TL. Transfer of interleukin 2 receptor genes into squamous cell carcinoma. Modification of tumor cell growth. Arch Otolaryngol Head Neck Surg, 1993; 119(11):1229-35.
191. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother, 2003; 52(5):281-96.
192. Kreitman RJ. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther, 2003; 5(1):44-51.
193. Klimka A, Barth S, Matthey B, Roovers RC, Lemke H, Hansen H et al. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer, 1999; 80(8):1214-22.
194. Wang L, Liu B, Schmidt M, Lu Y, Wels W, Fan Z. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate, 2001; 47(1):21-28.
195. Bruell D, Stocker M, Huhn M, Redding N, Kupper M, Schumacher P et al. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol, 2003; 23(4):1179-86.
196. Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer, 2000; 86(2):269-75.
197. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res, 2003; 9(7):2837-48.
198. Song LP, Cheng JL, Wang XB, Zhang Z, Fang M, Zhou ZY et al. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai), 2003: 35(6):503-10.
199. Jung G, Freimann U, Von Marschall Z, Reisfeld RA, Wilmanns W. Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol, 1991; 21(10):2431-35.
200. Curnow RT. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother, 1997; 45(3-4):210-15.
201. Arai S, Klingemann HG. Role of immunotherapy in stem cell transplantation. Int J Hematol, 2003; 77(1):22-28.
202. Chikamatsu K, Reichert TE, Kashii Y, Saito T, Kawashiri S, Yamamoto E et al. Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice. Int J Cancer, 1999; 82(4):532-37.
203. To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase I study. Arch Otolaryngol Head Neck Surg, 2000; 126(10):1225-31.
204. Livingstone AM, Kuhn M. Peptide-pulsed splenic dendritic cells prime long-lasting CD8(+) T cell memory in the absence of cross-priming by host APC. Eur J Immunol, 2002; 32(1):281-90.
205. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res, 2003; 63(19):6478-87.
206. Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother, 2004; 53(6):510-18.
207. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods, 1996; 196(2):121-35.
208. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trochenbacher B et al. Proliferating dendritic cell progenitors in human blood. J Exp Med, 1994; 180(1):83-93.
209. Caux C, Dezuffer-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature, 1992; 360(6401):258-61.
210. Chantry D, Turner M, Brennan F, Kingsbury A, Feldmann M. Granulocyte-macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. Cytokine, 1990; 2(1):60-67.
211. Kiertscher SM, Gitlitz BJ, Figlin RA, Roth MD. Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients. Int J Cancer, 2003; 107(2):256-61.
212. Roth MD, Gitlitz BJ. Kiertscher SM, Park AN, Mendenhall M, Moldawer N et al. Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res, 2000; 60(7):1934-41.
213. Khatami S, Brummer E, Stevens DA . Effects of granulocyte-macrophage colony stimulating factor (GM-CSF) in vivo on cytokine production and proliferation by spleen cells. Clin Exp Immunol, 2001; 125(2):198-201.
214. Gerrard TL, Dyer DR, Mostowski HS. IL-4 and granulocyte-macrophage colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but not HLA-DQ antigens on human monocytes. J Immunol, 1990; 144(12):4670-74.
215. Xu H, Kramer M, Spengler HP, Peters JH. Dendritic cells differentiated from human monocytes through a combination of IL-4, GM-CSF and IFN-gamma exhibit phenotype and function of blood dendritic cells. Adv Exp Med Biol, 1995; 378:75-78.
216. Luft T, Luetjens P, Hochrein H, Toy T, Masterman KA, Rizkalla M et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol, 2002, 14(4):367-80.
217. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol, 1998; 161(4):1947-53.
218. Satthaporn S, Al-Sarireh B, Robins A, Vassanasiri W, El-Sheemy M, Jibril J, Clark D, Valerio D, Eremin O. Reversal of defective dendritic cell function in vitro in women with operable breast cancer: important role of INF-α. In process citation, 2003.
219. Dauer M, Pohl K, Obermaier B, Meskendahl T, Robe J, Schnurr M, Endres S et al. Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation. Immunology, 2003; 110(1):38-47.
220. Alters SE, Gadea JR, Holm B, Lebkowski J, Philip R. IL-13 can substitute for IL-4 in the generation of dendritic cells for the induction of cytotoxic T lymphocytes and gene therapy. J Immunother, 1999; 22(3):229-36.
221. McRae BL, Nagai T, Semnani RT, van Seventer JM, van Seventer GA. Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors. Blood, 2000; 96(1):210-17.
222. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol, 2003; 21:685-711.
223. Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol, 2002; 104(1):14-20.
224. Gottfried E, Krieg R, Eichelberg C, Andreesen R, Mackensen A, Krause SW. Characterization of cells prepared by dendritic cell-tumor cell fusion, Cancer Immun, 2002; 2:15.
225. Lin CL, Lo WF, Lee TM, Ren Y, Hwang SL, Cheng YF et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res, 2002; 62(23):6952-58.
226. Sievers E, Albers P, Schmidt-Wolf IG, Marten A. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J Urol, 2004; 171(1):114-19.